Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis-Reference-Cited by-同舟云学术

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Published:2014-08-14 Issue:7 Volume:124 Page:1062-1069
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rumi Elisa¹²,Pietra Daniela¹,Pascutto Cristiana¹,Guglielmelli Paola³,Martínez-Trillos Alejandra⁴,Casetti Ilaria²,Colomer Dolors⁴,Pieri Lisa³,Pratcorona Marta⁴,Rotunno Giada³,Sant’Antonio Emanuela²,Bellini Marta²,Cavalloni Chiara²,Mannarelli Carmela³,Milanesi Chiara¹,Boveri Emanuela⁵,Ferretti Virginia¹,Astori Cesare¹,Rosti Vittorio⁶,Cervantes Francisco⁴,Barosi Giovanni⁶,Vannucchi Alessandro M.³,Cazzola Mario¹²

Affiliation:

1. Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico [IRCCS] Policlinico San Matteo, and

2. Department of Molecular Medicine, University of Pavia, Pavia, Italy;

3. Laboratorio Congiunto Malattie Mieloproliferative Croniche, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;

4. Hematology and Hematopathology Departments, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; and

5. Anatomic Pathology Section and

6. Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Abstract

Key Points Patients with PMF may carry JAK2 (V617F), a CALR exon 9 indel, an MPL exon 10 mutation, or none of these genetic lesions. The genetic subtypes of PMF differ substantially as regards clinical course, disease progression, and overall survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/7/1062/1382989/1062.pdf

Reference34 articles.

1. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.;Barosi;Blood,2001

2. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.;Cervantes;Blood,2009

3. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).;Passamonti;Blood,2010

4. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.;Cazzola;Blood,2014

Cited by 319 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms’;Current Research in Translational Medicine;2024-03

2. COMPARISON OF PATIENTS WITH PRE-DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASM PATIENTS WITH LOW AND HIGH JAK2V617F ALLELE BURDEN IN TERMS OF CLINICAL AND HEMATOLOGICAL PARAMETERS;Kocatepe Tıp Dergisi;2024-01-17

3. Immunophenotypic changes in NRBCs of Philadelphia chromosome-negative myeloproliferative neoplasms and its clinical significance;2024-01-12

4. Allogeneic Cell Transplantation for Myeloproliferative Neoplasms;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

5. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape;International Journal of Molecular Sciences;2023-12-12